Article
Hematology
Zhenhua Li, Ti-Cheng Chang, Jacob J. Junco, Meenakshi Devidas, Yizhen Li, Wenjian Yang, Xin Huang, Dale J. Hedges, Zhongshan Cheng, Mary Shago, Andrew J. Carroll, Nyla A. Heerema, Julie Gastier-Foster, Brent L. Wood, Michael J. Borowitz, Lauren Sanclemente, Elizabeth A. Raetz, Stephen P. Hunger, Eleanor Feingold, Tracie C. Rosser, Stephanie L. Sherman, Mignon L. Loh, Charles G. Mullighan, Jiyang Yu, Gang Wu, Philip J. Lupo, Karen R. Rabin, Jun J. Yang
Summary: This study investigates the genomics of Down syndrome-related acute lymphoblastic leukemia (DS-ALL) and identifies 15 molecular subtypes, as well as abnormal activation of key genes. It also reveals the common occurrence of somatic genomic abnormalities mediated by gene rearrangements in DS-ALL and the association between subtype heterogeneity and prognosis. These findings provide important insights into the biology of DS-ALL and offer opportunities for individualized treatment.
Review
Oncology
Oscar Molina, Maria Alba Abad, Francesc Sole, Pablo Menendez
Summary: Aneuploidy, characterized by the gain or loss of chromosomes in a cell, is a hallmark of cancer. While it is more common in solid tumors, it also plays a significant role in patients with B cell acute lymphoblastic leukemia (B-ALL). Research has shown that aneuploidy promotes tumor progression.
Review
Oncology
Francesco Tamiro, Andrew P. Weng, Vincenzo Giambra
Summary: Leukemia-initiating cells (LIC) are unique cells in different types of leukemia that have self-renewing capabilities and produce tumors, which are functionally distinct from bulk leukemia cells. Current conventional treatments are not effective in eliminating LICs, hence innovative therapeutics targeting LICs hold promise for developing an effective cure for ALL.
Article
Oncology
Uma Athale, Rinku Sutradhar, Vicky R. Breakey, Qing Li, Mylene Bassal, Paul Gibson, Serina Patel, Laura Wheaton, Jason D. Pole, Nicole Mittman, Petros Pechlivanoglou, Sumit Gupta
Summary: Children with Down syndrome and acute lymphoblastic leukemia require increased supportive care and experience higher healthcare utilization and treatment costs compared to non-Down syndrome patients. This study provides baseline data for future cost-effectiveness studies specific to Down syndrome.
PEDIATRIC BLOOD & CANCER
(2022)
Article
Clinical Neurology
Rui Li, Ji-Hong Tang, Bing-Bing Zhang, Xiao-Yan Shi, Yuan-Yuan Dai, Rui Qu
Summary: The clinical characteristics of epileptic seizures in children with acute lymphoblastic leukemia (ALL) during treatment were analyzed. Epileptic seizures mainly occurred in the induction remission period, maintenance treatment period, and after bone marrow transplantation. The common causes were MTX-related demyelinating encephalopathy and reversible posterior encephalopathy syndrome (PRES). Convulsion was the first symptom. Early neuroimaging and EEG examination are important for early diagnosis and treatment.
FRONTIERS IN NEUROLOGY
(2022)
Review
Biochemistry & Molecular Biology
Abdulrahman H. Almaeen, Mohamed Abouelkheir
Summary: CAR T-cell therapy is a new and successful treatment for acute lymphoblastic leukemia (ALL). However, it is expensive and associated with adverse effects. Ongoing development aims to improve efficacy and overcome limitations.
Article
Oncology
Theodore W. Laetsch, Shannon L. Maude, Adriana Balduzzi, Susana Rives, Henrique Bittencourt, Michael W. Boyer, Jochen Buechner, Barbara De Moerloose, Muna Qayed, Christine L. Phillips, Michael A. Pulsipher, Hidefumi Hiramatsu, Ranjan Tiwari, Stephan A. Grupp
Summary: This study evaluated the efficacy and side effects of tisagenlecleucel in DS-ALL patients and compared it with patients without DS. The results showed that tisagenlecleucel had similar remission rates and safety profiles in DS-ALL patients as in patients without DS.
Article
Oncology
Anna L. Hoppmann, Yanjun Chen, Wendy Landier, Lindsey Hageman, William E. Evans, F. Lennie Wong, Mary V. Relling, Smita Bhatia
Summary: The study measured 6MP adherence in children with ALL using electronic monitoring and developed a risk prediction model which can identify high-risk patients in real time for personalized interventions.
Article
Medicine, Research & Experimental
Rahul S. Bhansali, Malini Rammohan, Paul Lee, Anouchka P. Laurent, Qiang Wen, Praveen Suraneni, Bon Ham Yip, Yi-Chien Tsai, Silvia Jenni, Beat Bornhauser, Aurelie Siret, Corinne Fruit, Alexandra Pacheco-Benichou, Ethan Harris, Thierry Besson, Benjamin J. Thompson, Young Ah Goo, Nobuko Hijiya, Maria Vilenchik, Shai Izraeli, Jean-Pierre Bourquin, Sebastien Malinge, John D. Crispino
Summary: The study reveals that DYRK1A is overexpressed in and essential for B-ALL, with FOXO1 and STAT3 being critical substrates. Loss of DYRK1A-mediated FOXO1 and STAT3 signaling disrupts DNA damage and ROS regulation, leading to preferential cell death in leukemic B cells.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Nanoscience & Nanotechnology
Yaru Zou, Dong Mei, Jinjie Yuan, Jiaqi Han, Jiamin Xu, Ning Sun, Huan He, Changqing Yang, Libo Zhao
Summary: The study focused on constructing 6-mercaptopurine (6-MP)-loaded nanomedicines to enhance its anticancer efficacy for acute lymphoblastic leukemia (ALL) treatment. The results showed that the nanomedicines significantly improved the cytotoxicity in Jurkat cells and prolonged the survival time of ALL model mice, demonstrating their potential as a promising delivery strategy for 6-MP with reduced systemic toxicity.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Pharmacology & Pharmacy
Shuang Fu, Mengqi Li, Hongtao Wang
Summary: This article describes a rare case of a 29-year-old man diagnosed with acute promyelocytic leukemia (APL) in 2019, who developed BCR-ABL1-positive acute lymphoblastic leukemia (ALL) 2 years later. The patient responded well to tyrosine kinase inhibitors and chemotherapy, achieving a molecular remission. While APL generally has a good prognosis, the prognosis of its secondary malignancies is uncertain. There are no effective measures to prevent the occurrence of secondary tumors. Increasing the frequency of laboratory testing, especially molecular biomarker monitoring, is crucial for diagnosing and treating secondary malignancies after achieving complete remission.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Oncology
Zixi Hong, Zimeng Wei, Tian Xie, Lin Fu, Jiaxing Sun, Fuling Zhou, Muhammad Jamal, Qiuping Zhang, Liang Shao
Summary: Acute lymphoblastic leukemia (ALL) is regulated by various signaling molecules such as cytokines and adhesion molecules in its microenvironment. Chemokines play important roles in leukemia microenvironment and affect ALL outcomes. Targeting chemokine axes for ALL treatments shows potential, with some related inhibitors entering clinical trials.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Medicine, General & Internal
Khalil Saleh, Florence Pasquier, Camille Bigenwald, Stephane De Botton, Vincent Ribrag, Cristina Castilla-Llorente
Summary: B-cell acute lymphoblastic leukemia (B-ALL) is the most common subtype of acute leukemia in children. The prognosis and treatment of B-ALL have improved significantly in recent years. Novel immunologic agents and CAR T-cell therapy have achieved important breakthroughs in the treatment of B-ALL, but resistance remains a challenge.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Young Bae Choi, Keon Hee Yoo
Summary: This study investigated acute leukemia patients aged 0-19 years between 2007 and 2016 using the National Health Insurance Service database. The results showed that 1.1% of children with acute leukemia had Down syndrome (DS), and the DS group had a younger age at diagnosis and a higher proportion of acute myeloid leukemia. Furthermore, in Korea, the incidence of acute leukemia was higher in DS patients compared to non-DS patients, but the overall survival rate was comparable between the two groups.
CANCER RESEARCH AND TREATMENT
(2022)
Article
Hematology
Filipe Martins, Michael Kruszewski, Ilaria Scarpelli, Jacqueline Schoumans, Olivier Spertini, Michael Luebbert, Sabine Blum
Summary: Myelodysplastic syndromes (MDS) have a variable probability of transforming into acute leukemia, with rare cases of acute lymphoblastic leukemia reported in MDS patients. These atypical cases highlight the possibility of major phenotypic switches occurring during disease progression.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Amit Tirosh, Sanjit Mukherjee, Justin Lack, Sudheer Kumar Gara, Sophie Wang, Martha M. Quezado, Xavier M. Keutgen, Xiaolin Wu, Maggie Cam, Suresh Kumar, Dhaval Patel, Naris Nilubol, Monica Varun Tyagi, Electron Kebebew
Article
Oncology
Chandrayee Ghosh, Suresh Kumar, Yevgeniya Kushchayeva, Kelli Gaskins, Myriem Boufraqech, Darmood Wei, Sudheer Kumar Gara, Lisa Zhang, Ya-qin Zhang, Min Shen, Sanjit Mukherjee, Electron Kebebew
CLINICAL CANCER RESEARCH
(2020)
Article
Biochemistry & Molecular Biology
Shashank Shrishrimal, Arpita Chatterjee, Elizabeth A. Kosmacek, Paul J. Davis, J. Tyson McDonald, Rebecca E. Oberley-Deegan
FREE RADICAL BIOLOGY AND MEDICINE
(2020)
Article
Biochemistry & Molecular Biology
Arpita Chatterjee, Elizabeth A. Kosmacek, Shashank Shrishrimal, J. Tyson McDonald, Rebecca E. Oberley-Deegan
Article
Biochemistry & Molecular Biology
Yuxiang Zhu, Elizabeth A. Kosmacek, Arpita Chatterjee, Rebecca E. Oberley-Deegan
Article
Multidisciplinary Sciences
Ka Yun Tan, Avirup Dutta, Tze King Tan, Ranjeev Hari, Rofina Y. Othman, Siew Woh Choo
Meeting Abstract
Biochemistry & Molecular Biology
Arpita Chatterjee, Divya Murthy, Elizabeth Kosmacek, Pankaj Singh, Rebecca Oberley-Deegan
FREE RADICAL BIOLOGY AND MEDICINE
(2022)
Article
Oncology
Diane L. Costanzo-Garvey, Adam J. Case, Gabrielle F. Watson, Massar Alsamraae, Arpita Chatterjee, Rebecca E. Oberley-Deegan, Samikshan Dutta, Maher Y. Abdalla, Tammy Kielian, Merry L. Lindsey, Leah M. Cook
Summary: Bone metastatic prostate cancer (BM-PCa) is difficult to treat due to complex interactions between cancer and stromal cells. Neutrophils in the bone marrow have been found to elicit an anti-tumor immune response against BM-PCa. This study explores the importance of neutrophil oxidative burst in BM-PCa and suggests that targeting ROS and glutathione programming could be effective in inhibiting BM-PCa progression.
CLINICAL & EXPERIMENTAL METASTASIS
(2022)
Review
Physiology
Brigitta Buttari, Marzia Arese, Rebecca E. Oberley-Deegan, Luciano Saso, Arpita Chatterjee
Summary: Metabolic alterations are common survival mechanism for prostate cancer, with oxidative stress in the cellular and tumor microenvironment dictating metabolic switching in cancer cells. Regulation of oxidative stress may enhance conventional anticancer therapies.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Multidisciplinary Sciences
Molly S. Myers, Elizabeth A. Kosmacek, Arpita Chatterjee, Rebecca E. Oberley-Deegan
Summary: Prostate cancer is a common cancer in men in the United States. A study found that compared to bioluminescent imaging, CT imaging is more accurate in measuring the growth of orthotopic prostate cancer in mouse models.
Meeting Abstract
Oncology
C. Lin, J. Grem, K. Klute, J. Crapo, A. Filler-Katz, E. Doherty, S. Penchev, A. Chatterjee, E. A. Kosmacek, R. E. Oberley-Deegan
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Meeting Abstract
Biochemistry & Molecular Biology
Yuxiang Zhu, Elizabeth A. Kosmacek, Arpita Chatterjee, Rebecca E. Oberley-Deegan
FREE RADICAL BIOLOGY AND MEDICINE
(2020)
Meeting Abstract
Biochemistry & Molecular Biology
Arpita Chatterjee, Joshua A. McDowell, Elizabeth Kosmacek, Rebecca Oberley-Deegan
FREE RADICAL BIOLOGY AND MEDICINE
(2020)
Meeting Abstract
Biochemistry & Molecular Biology
Arpita Chatterjee, Elizabeth Kosmacek, Shashank Shrishirmal, Rebecca Oherley-Deegan
FREE RADICAL BIOLOGY AND MEDICINE
(2019)
Meeting Abstract
Endocrinology & Metabolism
A. Tirosh, S. Mukherjee, J. Lack, S. K. Gara, M. Quezado, X. M. Keutgen, M. Cam, S. Kumar, D. Patel, N. Nilubol, M. Tyagi, E. Kebebew
NEUROENDOCRINOLOGY
(2019)